Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. (16th April 2015)

• Record Type: Journal Article
• Authors: van de Kerkhof, P.C.M.; Reich, K.; Kavanaugh, A.; Bachelez, H.; Barker, J.; Girolomoni, G.; Langley, R.G.; Paul, C.F.; Puig, L.; Lebwohl, M.G.
• Is Part Of: Journal of the European Academy of Dermatology and Venereology. Volume 29:Number 10(2015:Oct.)
• Page Start: 2002
• Page End: 2010
• Publication Date: 2015-04-16
• Subjects: Dermatology -- Periodicals; Sexually transmitted diseases -- Periodicals; 616.5
• DOI: 10.1111/jdv.13150
• Languages: English
• ISSNs: 0926-9959

Abstract

<abstract abstract-type="main" id="jdv13150-abs-0001"> <title>Abstract</title> <sec id="jdv13150-sec-0001" sec-type="section"> <title>Background</title> <p>Available literature on psoriasis and psoriatic arthritis (PsA) demonstrates a tremendous burden of disease and suggests underdiagnosis and undertreatment.</p> </sec> <sec id="jdv13150-sec-0002" sec-type="section"> <title>Objective</title> <p>To obtain real‐world physician perspectives on the impact of psoriasis and PsA and its treatment on patients' daily lives, including perceptions of, and satisfaction with, current therapies.</p> </sec> <sec id="jdv13150-sec-0003" sec-type="section"> <title>Methods</title> <p>The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) surveyed dermatologists (<italic>n</italic> = 391) and rheumatologists (<italic>n</italic> = 390) in North America (Canada and the United States) and Europe (France, Germany, Italy, Spain and United Kingdom).</p> </sec> <sec id="jdv13150-sec-0004" sec-type="section"> <title>Results</title> <p>Dermatologists classified 20.3% and 25.7% of their patients as having severe psoriasis and severe PsA respectively; rheumatologists indicated that 48.4% of their PsA patients had active disease. Of the psoriasis patients complaining of joint pain, only 33.0% had a diagnosis of PsA. An impact on daily activities or social/emotional well‐being was recognized by 57.2% to 79.3% of physicians. In patients with moderate‐to‐severe psoriasis, dermatologists reported 74.9% were receiving topical therapy, 19.5% conventional oral therapy and 19.6% biologics. Dermatologists and rheumatologists reported similar rates of topical (≈45%) and biologic (≈30%) therapy utilization for their PsA patients; conventional oral therapy was more often prescribed by rheumatologists (63.4%) vs. dermatologists (35.2%). Reasons for not initiating or maintaining systemic therapies were related to concerns about long‐term safety, tolerability, efficacy and costs (biologics).</p> </sec> <sec id="jdv13150-sec-0005" sec-type="section"> <title>Conclusion</title> <p>Physicians in North America and Europe caring for patients with psoriasis and PsA acknowledge unmet treatment needs, largely concerning long‐term safety/tolerability and efficacy of currently available therapies; evidence suggests underdiagnosis of PsA and undertreatment of psoriasis among dermatologists.</p> </sec> </abstract>